Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI s Trent To Head Proposed Arizona Genomics Institute

NEW YORK, June 26-National Human Genome Research Institute scientific director Jeffrey Trent will head a new Translational Genomics Research Institute in Phoenix, Ariz., the governor of the state said today.

 

Trent, as president and chief executive officer, will be charged with developing the proposed research institute, which will focus on applying genomic discoveries into treatments for common diseases.

 

The institute is the brainchild of the University of Arizona, Northern Arizona University and Arizona State University. It comes as part of an effort by Arizona academic administrators, politicians and businesspeople to attract biotechnology research to the state.

 

Trent, a native Arizonan, was director of basic research at the Arizona Cancer Center in the 1980s.

 

It will be linked with the International Genomics Consortium, a nonprofit Arizona foundation that is working to generate a major public database of gene expression in normal and cancerous human tissues. Trent is the senior scientific advisor for that effort.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.